Loading
Everest Medicines Ltd. Stock: price and insider trades · Hong Kong
1 insider bought €87k of shares over the last 90 days, the latest by Wu Yifang, filed 14 Sept 2026.
Insider Decl.
85
Thresholds
n/a
Buy Volume
€306M
47 ops. · all time
Sell Volume
€425M
12 ops. · all time
Who traded when
BuySaleFu Wei11 buys4 sales
Wu Yifang12 buys
Luo Yongqing2 buys1 sale
Woo Ian Ying2 buys1 sale
Since the insiders bought
- +37.2%Entry HK$26.28 · Close 21 Oct 2026 HK$36.06
- +43.0%Entry HK$25.22 · Close 21 Oct 2026 HK$36.06
- -25.4%Entry HK$50.00 · Close at T+90 HK$37.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,147 of 26,280 companies
33.2
score / 100
Value26
Quality41
FCF yld-3.5%
Earn yld-2.4%
EV/EBITDA·
ROE-1.2%
Gross mgn69%
Net mgn-17%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$35.64
Analyst consensus
6 analysts2.00/5
HK$25.95Target HK$40.85(+15%)HK$70.03
Income statement
RevenueHK$1.7B
Gross profitHK$1.2B69% margin
EBITDA-HK$418.6M-25% margin
Net income-HK$297.8M-2.2% margin
Valuation
PER (forward)30.7x
P/Book1.7x
Beta1.54
Balance sheet & cash
Market capHK$12.6B
Total debtHK$926.3M
Free Cash Flow-HK$440.9M
Debt / Equity38%
Profitability & ownership
ROE-1.2%
ROA-1.1%
% insiders5.9%
% institutions42.1%
Last declaration on 14 September 2026
Declarations85 total
8,000 shares@ HK$26.900.0018% mcap0.3% of flowShareXHKGHKEX:DA20260914E00100
Canonical exit: 10 Dec 2026 (T+90)
20,000 shares@ HK$28.70650.0048% mcap0.9% of flowShareXHKGHKEX:DA20260911E00107
Canonical exit: 9 Dec 2026 (T+90)
110,900 sharesShareXHKGHKEX:DA20260819E00119
52,877 sharesShareXHKGHKEX:DA20260819E00125
510,000 shares@ HK$27.28250.14% mcap1.3% of flowShareXHKGHKEX:DA20260622E00586
Canonical exit: 15 Sept 2026 (T+90)
202,000 shares@ HK$26.26790.052% mcap0.5% of flowShareXHKGHKEX:DA20260616E00548
Canonical exit: 14 Sept 2026 (T+90)
179,000 shares@ HK$27.880.050% mcap0.5% of flowShareXHKGHKEX:DA20260610E00493
Canonical exit: 6 Sept 2026 (T+90)
500,000 shares@ HK$27.89980.14% mcap1.3% of flowShareXHKGHKEX:DA20260610E00494
Canonical exit: 7 Sept 2026 (T+90)
690,000 shares@ HK$28.92760.20% mcap1.8% of flowShareXHKGHKEX:DA20260605E00457
Canonical exit: 1 Sept 2026 (T+90)
20,000 shares@ HK$28.800.0057% mcap1.1% of flowShareXHKGHKEX:DA20260605E00035
Canonical exit: 2 Sept 2026 (T+90)
224,000 shares@ HK$33.13440.073% mcap0.7% of flowShareXHKGHKEX:DA20260526E00551
Canonical exit: 19 Aug 2026 (T+90)
376,500 shares@ HK$31.18829.59% mcap89.1% of flowShareXHKGHKEX:DA20260525E00197
Canonical exit: 18 Aug 2026 (T+90)
20,000 shares@ HK$30.530.50% mcap94.6% of flowShareXHKGHKEX:DA20260519E00420
Canonical exit: 17 Aug 2026 (T+90)
660,000 shares@ HK$31.25170.20% mcap1.9% of flowShareXHKGHKEX:DA20260519E00172
Canonical exit: 12 Aug 2026 (T+90)
9,000 shares@ HK$31.160.0027% mcap0.5% of flowShareXHKGHKEX:DA20260513E00548
Canonical exit: 11 Aug 2026 (T+90)
9,500 shares@ HK$32.660.0030% mcap0.6% of flowShareXHKGHKEX:DA20260511E00096
Canonical exit: 6 Aug 2026 (T+90)
10,000 shares@ HK$35.260.0034% mcap0.7% of flowShareXHKGHKEX:DA20260429E00497
Canonical exit: 28 Jul 2026 (T+90)
5,500 shares@ HK$35.380.0019% mcap0.4% of flowShareXHKGHKEX:DA20260428E00253
Canonical exit: 26 Jul 2026 (T+90)
860,000 shares@ HK$38.11460.33% mcap3.0% of flowShareXHKGHKEX:DA20260331E00089
Canonical exit: 25 Jun 2026 (T+90)
120,000 sharesShareXHKGHKEX:DA20260331E00305
100,000 sharesShareXHKGHKEX:DA20260331E00324
11,500 shares@ HK$35.640.0041% mcap0.8% of flowShareXHKGHKEX:DA20260331E00333
Canonical exit: 25 Jun 2026 (T+90)
30,000 shares@ HK$37.981.7% of flowShareXHKGHKEX:DA20260102E00146
Canonical exit: 31 Mar 2026 (T+90)
339,000 shares@ HK$44.77030.2% of flowShareXHKGHKEX:DA20251220E00026
Canonical exit: 12 Mar 2026 (T+90)
132,500 shares@ HK$45.34100.0% of flowShareXHKGHKEX:DA20251216E00137
Canonical exit: 12 Mar 2026 (T+90)
25 of 85 declarations
About Everest Medicines Ltd.
Purchases dominate at Everest Medicines Ltd., a healthcare company listed in Hong Kong and valued at HKD 12.6 billion: 47 purchases against 12 sales, or 80% of market trades. Of the 85 filings published between October 22, 2020 and September 14, 2026, 27 fall in the last twelve months, including 23 purchases and no sale.
The most significant trades are all signed by director Fu Wei: purchases on August 1, 2025 and May 20, 2026, sales on July 30, 2025, June 17, 2025 and January 10, 2025. Director Wu Yifang bought EUR 5,551,020 on May 19, 2026 and has 12 filings, all of them purchases. On April 1, 2022, 6 insiders filed purchases on the same day.
Read moreShow less
Four filers share most of the record: Woo Ian Ying (21 filings), Fu Wei (19), Luo Yongqing (14) and Wu Yifang (12). Activity is concentrated in 2022 (20 filings), 2025 (19) and 2026 (23). Filings come out a median of 5 days after the trade. For 22 purchases a 90-day result is stored: median -11.5%, 32% positive (stored past results, not a forecast).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
